{"id":"W2947599368","doi":"10.1200/jco.2019.37.15_suppl.tps9599","title":"ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Baker Hughes (Canada); University Health Network","funders":"","keywords":"Ipilimumab; Medicine; Melanoma; Internal medicine; Oncology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Progressive disease; Combination therapy; Phases of clinical research; Adjuvant therapy; Randomized controlled trial; Gastroenterology; Immunotherapy; Clinical trial; Chemotherapy; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002059438,0.002123031,0.00267703,0.0005567338,0.0005462265,0.00128983,0.001179408,0.001969603,0.009205359],"category_scores_gemma":[0.001360966,0.0008977725,0.001969701,0.00051566,0.001418699,0.00125214,0.0005954686,0.003672683,0.001809912],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000938944,"about_ca_system_score_gemma":0.001679327,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001026635,"about_ca_topic_score_gemma":0.002555106,"domain_scores_codex":[0.9992494,0.0004133333,0.00002915495,0.0001230175,0.00006001064,0.0001249516],"domain_scores_gemma":[0.9989894,0.0002018364,0.0002175772,0.00006967859,0.00006229375,0.0004592139],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.963674,0.01455019,0.0007338676,0.0004171586,0.0005613856,0.00005579253,0.00007113442,0.0004334947,0.006861139,0.0001126352,0.001481878,0.01104723],"study_design_scores_gemma":[0.8684515,0.127496,0.001861232,0.00002122034,0.0002411718,0.00006044103,0.00002590884,0.0004061133,0.0004346926,0.0001326407,0.0008497592,0.00001922383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775439,0.002083431,0.0008675255,0.0009118476,0.0005048208,0.01055054,0.002709234,0.0002753798,0.00455337],"genre_scores_gemma":[0.9732416,0.001493921,0.002232621,0.002326817,0.0004604575,0.01172664,0.003110423,0.00008006368,0.005327362],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009205359,"threshold_uncertainty_score":0.03079504,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02516898557946562,"score_gpt":0.3730638883808516,"score_spread":0.347894902801386,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}